A healthy 8-year-old boy presented to our dermatology clinic with a 4-week history of worsening movement limitation and pain due to skin retraction of the right axilla. There were no constitutional ...

Brentuximab vedotin is currently funded only for people whose lymphoma has returned or has not responded to earlier treatment. Using brentuximab vedotin earlier is expected to support better outcomes ...

Anaplastic large cell lymphoma (ALCL), a distinct subtype of T-cell non-Hodgkin lymphoma, has been the subject of vigorous research efforts over recent years. Investigations have focused on improving ...

“Under today’s proposal, brentuximab could be used as a first treatment option for people newly diagnosed with sALCL.

Implant rupture must be ruled out in the presence of a large fluid effusion surrounding the implant. Effusions that develop within 1 year of surgery may indicate a postsurgical hematoma or effusion, ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system. Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell ...